CD8A and neoplasm: The bezafibrate and PD-1 blockade combination activates mitochondrial biogenesis and FAO in CD8+ T cells, enhances survival and proliferation of tumor-reactive cytotoxic T lymphocytes (CTLs), and improves the efficacy of PD-1 blockade against unresponsive tumors with systemic immunosuppressive properties (75).